Reaction
Myocardial Injury reporting signals
As of the last recalculation, Myocardial Injury appears in 981 FAERS reports alongside 26 co-occurring drug terms. The strongest observed disproportionality signal is NOREPINEPHRINE (PRR 38.4).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Norepinephrine | 19 | 38.4 | 38.5 |
| Norepinephrine Bitartrate | 22 | 33.1 | 33.2 |
| Oxaliplatin | 83 | 25.8 | 25.9 |
| Fluorouracil Cream, 0.5% | 73 | 21.9 | 21.9 |
| Fluorouracil | 73 | 21.6 | 21.6 |
| Dextrose | 13 | 21.2 | 21.2 |
| Dextrose Monohydrate | 13 | 20.9 | 20.9 |
| Polatuzumab Vedotin | 9 | 19.7 | 19.8 |
| Colchicine | 20 | 16.4 | 16.4 |
| Blinatumomab | 8 | 16.4 | 16.4 |
| Dexamethasone Sodium Phosphate | 7 | 14.7 | 14.7 |
| Fentanyl Citrate | 12 | 14.4 | 14.4 |
| Propofol | 24 | 14.3 | 14.3 |
| Sevoflurane | 5 | 12.8 | 12.8 |
| Osimertinib | 19 | 12.8 | 12.8 |
| Rocuronium Bromide | 7 | 12.7 | 12.7 |
| Pemetrexed | 12 | 12.0 | 12.0 |
| Atezolizumab | 18 | 10.0 | 10.0 |
| Trastuzumab | 30 | 9.5 | 9.5 |
| Pembrolizumab | 44 | 9.2 | 9.2 |
| Paclitaxel (Aibumin-Bound) | 33 | 8.8 | 8.8 |
| Pertuzumab | 11 | 8.7 | 8.7 |
| Durvalumab | 8 | 8.4 | 8.4 |
| Pemetrexed Disodium | 14 | 7.9 | 7.9 |
| Obinutuzumab | 6 | 7.8 | 7.8 |
| Carfilzomib | 9 | 6.8 | 6.8 |